A145 EFFICACY AND SAFETY OF UPADACITINIB MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM A RANDOMIZED PHASE 3 STUDY

BACKGROUND: Upadacitinib (UPA), an oral selective and reversible JAK inhibitor, demonstrated significantly greater efficacy compared with placebo (PBO) for induction of remission in patients with moderately to severely active ulcerative colitis (UC) in two phase 3 induction trials. AIMS: Evaluate sa...

Descripción completa

Detalles Bibliográficos
Autores principales: Panaccione, R, Danese, S, Zhouwen, W, Pangan, A, Hébuterne, X, Nakase, H, D’Haens, G, Panes, J, Lindsay, J, Higgins, P, Loftus, E, Sandborn, W, Xie, W, Sanchez gonzalez, Y, Liu, J, Weinreich, M, Vermeire, S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Poster of Distinction
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8859192/
http://dx.doi.org/10.1093/jcag/gwab049.144

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8859192/
http://dx.doi.org/10.1093/jcag/gwab049.144

Ejemplares similares